Why the study?
Does angiotensin receptor-neprilysin inhibitor (ARNi) improve renal outcomes compared to renin-angiotensin-aldosterone system inhibition?
Does angiotensin receptor-neprilysin inhibitor (ARNi) improve renal outcomes compared to renin-angiotensin-aldosterone system inhibition?
ARNi demonstrates superior renal safety and efficacy compared to RAAS inhibitors, preserving eGFR without increasing hyperkalemia risk.
Answers are grounded in this paper and cite their sources.
Supports ARNi preference for renal preservation in HF; challenges prior low-certainty evidence against benefit.
Available evidence supports the effectiveness of ARNi on improving renal outcome. Compared with renin-angiotensin-aldosterone system inhibition, ARNi protects against renal impairment, since ARNi users have a lower risk of renal dysfunction and a higher eGFR, without an increased risk of hyperkalemia. However, its benefit for CKD patients still warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: